1 U.S. lawmaker has disclosed 1 Achievision Biotech and Inc trade under the STOCK Act — 1 buy and 0 sells in 2018. Congress has been net buyers of ACHV.
*Notional-weighted price return on lawmakers' disclosed buys of ACHV, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2018-12-06 | Kurt Schrader | BUY | $1K–$15K | $29.60 | $8.18 2026-08-27 | -72.4% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
1 member of the U.S. House and Senate has disclosed Achievision Biotech and Inc transactions under the STOCK Act — 1 purchase and 0 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a ACHV purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Every ACHV trade is marked to the latest close in the Return column; sells matched to a prior buy show a realized round-trip return.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded ACHV and how it performed.